

**On-line Table: Univariate analysis and distribution of patient characteristics, laboratory values, procedure times, and imaging data in patients with favorable and unfavorable outcomes**

Patient Characteristics	Patients (n = 220)	Unfavorable Outcome (mRS 4–6) (n = 123)	Favorable Outcome (mRS 0–3) (n = 97)	P Value
Baseline clinical characteristics and laboratory results				
Age (yr) (mean) (SD)	71 (13)	74 (12)	68 (13)	.002 <sup>a</sup>
Male (No.) (%)	116 (52.7)	66 (56.9)	50 (43.1)	.787 <sup>b</sup>
Hypertension (No.) (%)	171 (77.7)	71 (41.5)	100 (58.5)	.100 <sup>b</sup>
Diabetes mellitus (No.) (%)	52 (23.6)	34 (65.4)	18 (34.6)	.113 <sup>b</sup>
Atrial fibrillation (No.) (%)	103 (47.3)	70 (57.9)	33 (34)	.001 <sup>b</sup>
Coronary artery disease (No.) (%)	66 (30)	42 (63.6)	24 (36.4)	.076 <sup>b</sup>
Hypercholesterolemia (No.) (%)	80 (36.4)	43 (53.8)	37 (46.3)	.777 <sup>b</sup>
History of smoking (No.) (%)	27 (12.3)	15 (55.6)	12 (44.4)	.839 <sup>b</sup>
Previous stroke (No.) (%)	55 (25)	37 (67.3)	18 (32.7)	.042 <sup>b</sup>
Prestroke mRS (median) (IQR)	0 (0–2)	1 (0–2)	0 (0–1)	.001 <sup>c</sup>
Initial NIHSS score (median) (IQR)	18 (15–21)	20 (15.5–22)	16 (11–19.25)	<.001 <sup>c</sup>
Systolic blood pressure on admission (mean) (SD) (mm Hg)	157 (29)	157 (32)	157 (26)	.961 <sup>a</sup>
Blood sugar on admission (mean) (SD) (mg/dL)	135 (65)	147 (80)	119 (33)	.001 <sup>a</sup>
HbA1c (mean) (SD) (%)	5.99 (1.31)	6.2 (1.7)	5.8 (0.7)	.028 <sup>a</sup>
Creatinine (mean) (SD) (mg/dL)	1.03 (0.66)	1.08 (0.51)	0.97 (0.8)	.200 <sup>a</sup>
Radiologic findings and procedural aspects				
Occlusion site				
ICA (excluding carotid-T) (No.) (%)	9 (4.1%)	5 (2.3)	4 (1.8)	.263 <sup>b</sup>
Tandem occlusion (cervical ICA and carotid-T/M1) (No.) (%)	27 (12.3%)	14 (6.4)	13 (5.9)	
Carotid-T (No.) (%)	59 (26.8)	38 (17.2)	21 (9.5)	
M1 (No.) (%)	99 (45)	54 (24.5)	45 (20.5)	
M2 (No.) (%)	26 (11.8)	12 (5.5)	14 (6.4)	
Hyperdense vessel sign on NCCT (No.) (%)	127 (57.7)	79 (62.2)	48 (37.8)	.039 <sup>b</sup>
e-ASPECTS (median) (IQR)	9 (8–10)	8 (7–10)	9 (8–10)	.014 <sup>c</sup>
Intravenous rtPA (No.) (%)	147 (66.8)	83 (56.5)	64 (43.5)	.886 <sup>b</sup>
Onset-to-treatment time (mean) (SD) (min)	160 (115)	161 (115)	160 (116)	.961 <sup>a</sup>
Door-to-needle time (mean) (SD) (min)	59 (118)	72 (153)	43 (25)	.173 <sup>a</sup>
Door-to-groin puncture time (mean) (SD) (min)	115 (67)	118 (60)	113 (76)	.617 <sup>a</sup>
General anesthesia during MT (No.) (%)	195 (88.6)	79 (40.5)	116 (59.5)	.005 <sup>b</sup>
Modern stent retriever (No.) (%)	198 (90)	88 (44.4)	110 (55.6)	.467 <sup>b</sup>
Recanalization (TICI 2b–3) (No.) (%)	147 (66.8)	64 (43.5)	83 (65.5)	<.0001 <sup>b</sup>
sICH (No.) (%)	14 (6.4%)	13 (1.6)	1 (1)	.004 <sup>b</sup>

**Note:**—HbA1c indicates hemoglobin A1c; IQR, interquartile range.

<sup>a</sup> Unpaired t test.

<sup>b</sup> Fisher exact test.

<sup>c</sup> Mann-Whitney U test.